Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsORALStandard

INVOKAMET XR

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Standard Dose
50MG;1GM
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription

Key Takeaways

  • Primary indication: Review priority: PRIORITY Marketing status: Prescription
  • Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA).
  • Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.